PVLA Stock Summary and Trading Ideas (Palvella Therapeutics | NASDAQ:PVLA)

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.

Palvella Therapeutics trades on the NASDAQ stock market under the symbol PVLA.

As of April 3, 2025, PVLA stock price declined to $24.43 with 78,959 million shares trading.

PVLA has a beta of -2.02, meaning it tends to be less sensitive to market movements. PVLA has a correlation of 0.12 to the broad based SPY ETF.

PVLA has a market cap of $274.14 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that PVLA belongs to (by Net Assets): VXF, AVSC, DFAC.

PVLA support price is $25.24 and resistance is $28.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PVLA shares will trade within this expected range on the day.